Effect of a combination of gemfibrozil and niacin on lipid levels

Journal of Clinical Pharmacology

Volumn 36, Issue 8, 1996, Pages 696-700

  Spencer, Gregory A ^a,b   Wirebaugh, Stewart ^a   Whitney, Edwin J ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b 59MDW/PSMM ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE;

EID: 0029792297     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04237.x     Document Type: Article

References (28)

1. American Heart Association: Heart and Stroke Facts. Dallas: American Heart Association, 1992.
2. Turpeinen O: Effect of cholesterol lowering diet on mortality from coronary heart disease and other causes. Circulation 1979; 59:1-7.
3. Hjermann I, Velve Byre K, Holme I: Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial of healthy men. Lancet 1981; 1303-1310.
4. Morrison LM: Diet in coronary atherosclerosis. JAMA 1960; 173: 884-888.
5. Dayton S, Pearce ML, Goldman H, Harnish A, Plotkin D, Shickman M, et al: Controlled trial of a diet high in unsaturated fat for prevention of arthrosclerotic complications. Lancet 1968; 2:1060-1062.
6. Oliver MF and the Research Committee of the Scottish Society of Physicians: Ischemic heart disease: a secondary prevention trial using clofibrate. Br Med J 1971; 4:775-784.
7. Rosenhamer G, Carlson LA: Effect of combined clofibrate-nicotinic acid treatment in ischemic heart disease. Atherosclerosis 1980; 37:129-138.
8. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsolmi P, Helo P: The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle age men with dyslipidemia. N Eng J Med 1987; 317:1237-1245.
9. Rifkind B: The lipid research clinic's coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease using cholestyramine: report from the committee of principal investigators. JAMA 1984; 251:251-264.
10. Coronary Drug Project Research Group: Clofibrate and niacin in heart disease. JAMA 1975; 231:360-381.
11. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apoprotein B. N Engl J Med 1990; 323:1289-1298.
12. Ginsburg GS, Safran C, Pasternak RC: Frequency of low serum high-density lipoprotein cholesterol in hospitalized patients with desireable total cholesterols. Am J Cardiol 1991; 68:187-192.
13. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdaian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256:2835-2838.
14. Keys A: Alpha lipoprotein (HDL) cholesterol in the serum and risk of coronary artery disease and death. Lancet 1980; 2:603-606.
15. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotien as a protective factor and the risk of coronary heart disease: The Framingham Study. Am J Med 1977; 62:707-714.
16. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023.
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
18. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH: Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63:42H-47H.
19. Litin SC, Anderson CF: Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989; 86:481-483.
20. Patterson DJ, Dew EW, Gyorkey F, Graham DY: Niacin hepatitis. South Med J 1983; 76:239-241.
21. Christensen NA, Achor RWP, Berge KG, Mason HL: Nicotinic acid treatment of hypercholesterolemia: a comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961; 177:76-80.
22. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanisms of action. Metabolism 1985; 34:642-650.
23. Mullin GE, Greenson JK, Mitchell MC: Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111:253-255.
24. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W: Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989; 164:725-729.
25. Wirebaugh SR, Whitney EJ: Long-term compliance with lipid-lowering therapy: one center's approach. Pharm Ther 1993; 6:559-571.
26. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 1991; 151:1873-1874.
27. Carlson LA, Rosenhammer G: Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.
28. LaRosa JC: Combinations of drugs in lipid lowering therapy. Am J Med 1994; 96:399-400.